TrialJournal for immunotherapy of cancer2021

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.

Josep Malvehy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.